Detalhe da pesquisa
1.
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.
Cancer
; 126(24): 5247-5255, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32975815